These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35091711)

  • 1. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
    Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
    Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
    Yang X; Allen JC; Aslim EJ; Tay KJ; Yuen SPJ; Kanesvaran R; Chua MLK; Chong TW; Ho SSH; Lee LS
    Int J Urol; 2022 Nov; 29(11):1322-1330. PubMed ID: 36000794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    Shore N; Hafron J; Saltzstein D; Brown G; Belkoff L; Aggarwal P; Phillips J; Bhaumik A; McGowan T
    J Urol; 2024 Nov; 212(5):682-691. PubMed ID: 39088398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
    McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
    Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
    Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM
    Clin Cancer Res; 2023 Oct; 29(19):3867-3874. PubMed ID: 37439809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
    Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
    Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
    McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.
    Wang B; Pan J; Zhang T; Ni X; Wei Y; Li X; Fang B; Hu X; Gan H; Wu J; Wang H; Ye D; Zhu Y
    BMC Cancer; 2024 May; 24(1):643. PubMed ID: 38796422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group.
    Ilario EN; Bastos DA; Guglielmetti GB; Murta CB; Cardili L; Cordeiro MD; Junior JP; Coelho RF; Nahas WC
    Clin Genitourin Cancer; 2023 Feb; 21(1):43-54. PubMed ID: 36428171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
    Hahn AW; Manyam GC; Chapin BF; Zhang M; Yu Y; Pettaway CA; Chery L; Pisters LL; Ward JF; Gregg JR; Papadopoulos J; Kamat AM; Lozano M; Hoang A; Broom B; Wang X; Huff CD; Logothetis CJ; Troncoso P; Pilié PG; Davis JW
    BJU Int; 2024 Sep; 134(3):449-458. PubMed ID: 38837608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
    BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
    Zhang T; Howard L; Koontz BF; Tagawa ST; Nagar H; Bitting RL; Frizzell BA; Nordquist L; Rasmussen J; Riggan C; Reyes M; Davies C; Gray SR; Newman CR; Fernandez E; Ramalingam S; Harrison MR; George DJ; Wu Y; Armstrong AJ
    Eur Urol Oncol; 2024 Jul; ():. PubMed ID: 38971644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
    Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
    Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
    Katz MS; Zelefsky MJ; Venkatraman ES; Fuks Z; Hummer A; Leibel SA
    J Clin Oncol; 2003 Feb; 21(3):483-9. PubMed ID: 12560439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
    Dirix P; Strijbos M; den Mooter TV; Liefhooghe N; Bruwaene SV; Uvin P; Ghysel C; Ost D; Schatteman P; Bral S; Engels B; den Begin RV; Otte FX; Roumeguere T; Palumbo S; Neybuch Y; Fonteyne V; Ost P; Dirix L
    Future Oncol; 2020 Jun; 16(16):1083-1189. PubMed ID: 32356465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
    Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
    Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.